FDA Will Peel Back Another Layer Of GMP Compliance In 2013
This article was originally published in The Tan Sheet
FDA will take GMP inspections beyond the basics in 2013, experts agree. Firms can expect more inspections, deeper dives from reviewers and tougher consequences.
You may also be interested in...
GMP inspectors will begin more aggressively enforcing requirements for ingredient and contaminant specifications, FDA’s Fabricant warns. Recalls for undeclared allergens, salmonella and other pathogens are emerging more frequently as well.
FDA enforcement of the good manufacturing practices final rule causes some in the supplement industry to question whether small and medium-sized firms can manufacture in-house successfully. Meanwhile, third-party manufacturers are realizing the benefits of a tighter regulatory environment.
The Montreal pharma company includes a focus on OTCs and generics in its quest to grow while remaining relatively immune to patent cliffs and scaled-back Rx reimbursements. Valeant’s recent PEDiNOL Pharmacal acquisition, including OTC podiatry products, fits into its niche category strategy.